Trials / Completed
CompletedNCT06511570
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
A Phase 1, Open-Label Study Comparing the Safety, Tolerability, and Pharmacokinetics of Single-Dose Intravenous Sabirnetug (ACU193) and Multiple-Dose Subcutaneous Sabirnetug (ACU193) + rHuPH20 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Acumen Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sabirnetug (ACU193) | sabirnetug by intravenous infusion |
| COMBINATION_PRODUCT | Sabirnetug + rHuPH20 | sabirnetug + rHuPH20 by subcutaneous injection |
Timeline
- Start date
- 2024-06-25
- Primary completion
- 2024-09-17
- Completion
- 2024-09-17
- First posted
- 2024-07-22
- Last updated
- 2024-10-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06511570. Inclusion in this directory is not an endorsement.